SCHEMBL4375640

SCHEMBL4375640

COc1cc2c(Oc3ccc(Br)cc3F)ncnc2cc1OCCCNS(C)(=O)=O

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 1/20 0.54
ENPP1 P22413 2/20 0.52
KDR P35968 10/20 0.49
EGFR P00533 9/20 0.49
FLT1 P17948 3/20 0.49
FLT4 P35916 3/20 0.49
RET P07949 1/20 0.48
KIF5B P33176 1/20 0.48
FGFR1 P11362 2/20 0.47
BRD4 O60885 1/20 0.46
ERBB2 P04626 1/20 0.46
ERBB4 Q15303 1/20 0.46
PDGFRB P09619 1/20 0.46
FGFR2 P21802 1/20 0.46
FGFR4 P22455 1/20 0.46
FGFR3 P22607 1/20 0.46
MET P08581 3/20 0.45
KIT P10721 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6100586 0.85 TRPA1 (0.53) TRPA1KDREGFRFLT1FLT4
SCHEMBL4375675 0.85 TRPA1 (0.63) TRPA1KDREGFRFLT1FLT4
SCHEMBL4421666 0.85 TRPA1 (0.63) TRPA1KDREGFRFLT1FLT4
SCHEMBL4374479 0.82 AXL (0.56) TRPA1KDREGFRFLT1FLT4
SCHEMBL4421590 0.78 TRPA1 (0.61) TRPA1KDREGFRFLT1FLT4
SCHEMBL4420668 0.77 KDR (0.61) TRPA1KDREGFRFLT1FLT4
SCHEMBL25656033 0.77 ENPP1 (0.81) ENPP1KDREGFRRETMET
SCHEMBL4374482 0.77 TRPA1 (0.50) TRPA1KDREGFRFLT1FLT4
SCHEMBL4692996 0.76 TRPA1 (0.59) TRPA1KDREGFRFLT1FLT4
SCHEMBL4375838 0.75 TRPA1 (0.62) TRPA1KDREGFRFLT1FLT4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8492560-B2 Quinazoline derivatives as angiogenesis inhibitors ASTRAZENECA AB (SE) 2013-07-23 US disclosed
US-20120197027-A1 Quinazoline Derivatives as Angiogenesis Inhibitors STOKES ELAINE S E (GB) 2012-08-02 US disclosed
EP-2050744-A1 Quinazoline derivatives as angiogenesis inhibitors AstraZeneca AB (SE) 2009-04-22 EP disclosed
US-7074800-B1 Quinazoline derivatives as angiogenesis inhibitors ASTRAZENECA AB (SE) 2006-07-11 US disclosed
US-20060004017-A1 Quinazoline derivatives as angiogenesis inhibitors ASTRAZENECA AB 2006-01-05 US disclosed
EP-1553097-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AND INTERMEDIATES THEREFORE AstraZeneca AB (SE) 2005-07-13 EP disclosed
EP-1154774-B1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS ASTRAZENECA AB (SE) 2005-06-22 EP disclosed
EP-1154774-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AstraZeneca AB (SE) 2001-11-21 EP disclosed
WO-2000047212-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS ASTRAZENECA AB (SE) 2000-08-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120197027-A1 Quinazoline Derivatives as Angiogenesis Inhibitors VEGFA, FLT1, KDR TRPA1 2422/4885ENPP1 2575/4885KDR 3/4885
US-20060004017-A1 Quinazoline derivatives as angiogenesis inhibitors FLT4, NOS3, FLT1 TRPA1 4692/4885ENPP1 4133/4885KDR 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.